Is Quest Diagnostics (DGX) Using At-Home STI Tests to Redefine Its Consumer Health Strategy?

• In November 2025, Visby Medical announced that Quest Diagnostics’ consumer platform, questhealth.com, added the FDA-authorized at-home Visby Women’s Sexual Health Test for rapid STI detection, expanding national access to 30-minute, at-home PCR testing for chlamydia, gonorrhea, and trichomoniasis.
• This move highlights Quest’s push into consumer-initiated women’s health testing, addressing significant gaps in timely STI diagnosis and treatment that can affect fertility.
• Next, we’ll examine how this expansion into at-home women’s STI testing may influence Quest Diagnostics’ broader investment narrative and growth drivers.

The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer’s.

Quest Diagnostics Investment Narrative Recap

To own Quest Diagnostics, you need to believe in steady demand for diagnostic testing, particularly in advanced and preventive care, while keeping an eye on reimbursement and payer mix pressures. The addition of Visby’s at-home Women’s Sexual Health Test fits Quest’s push into consumer-initiated testing, but it is unlikely to meaningfully change the key near term catalyst, which remains execution against its existing growth and margin targets, or the primary risk around potential reimbursement cuts and payer pressure.

The most relevant recent announcement alongside this Visby news is Quest’s plan to report Q4 2025 results on February 10, 2026, which will give investors a clearer view of how its mix of advanced testing, consumer offerings and cost initiatives is tracking against guidance. That update will matter more for the investment case than this single product addition, even though both tie back to the same theme of building more resilient, recurring testing demand.

However, investors should also be aware that persistent pricing pressure and reimbursement risk could still…

Read the full narrative on Quest Diagnostics (it’s free!)

Quest Diagnostics’ narrative projects $11.9 billion revenue and $1.3 billion earnings by 2028. This requires 4.1% yearly revenue growth and about a $355 million earnings increase from $945.0 million today.

Uncover how Quest Diagnostics’ forecasts yield a $198.06 fair value, a 5% upside to its current price.

Exploring Other Perspectives

Three Simply Wall St Community fair value estimates for Quest range from US$157.30 to US$224.73, showing how far apart individual views can be. Against that spread, the risk of tighter reimbursement and payer pressure becomes a key variable that could influence how those different valuation opinions play out over time, so it is worth exploring several viewpoints before forming a view of your own.

Explore 3 other fair value estimates on Quest Diagnostics – why the stock might be worth as much as 19% more than the current price!

Build Your Own Quest Diagnostics Narrative

Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

Ready To Venture Into Other Investment Styles?

Our top stock finds are flying under the radar-for now. Get in early:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]